Cover Image

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis

Edgar Carnero Contentti,1 Jorge Correale2,3 1Neuroimmunology Unit, Department of Neuroscience, Hospital Alemán, Buenos Aires, Argentina; 2Department of Neurology, Fleni, Buenos Aires, Argentina; 3Universidad de Buenos Aires-CONICET, Instituto de Química y Fisicoquimí...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carnero Contentti E (Author), Correale J (Author)
Format:	Book
Published:	Dove Medical Press, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
by: Timothy J. Turner, et al.
Published: (2024)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017)

The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma
by: Qiuni Chen, et al.
Published: (2024)

Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives
by: Lorefice L, et al.
Published: (2023)

Pediatric multiple sclerosis: current perspectives on health behaviors
by: Sikes EM, et al.
Published: (2018)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
by: Rachael Arthur, et al.
Published: (2020)

ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
by: Krishnarup Ghoshdastidar, et al.
Published: (2020)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
by: Correale J, et al.
Published: (2016)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
by: Jing Zhang, et al.
Published: (2022)

Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
by: Tony Eight Lin, et al.
Published: (2022)

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod
by: Correale J, et al.
Published: (2014)

Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives
by: Fengna Chu, et al.
Published: (2018)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
by: Qing Wan, et al.
Published: (2022)

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
by: Ying C. Ou, et al.
Published: (2021)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
by: Alexander P. de Porto, et al.
Published: (2019)

Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
Published: (2017)

A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects
by: Ehsanollah Esfandiari, et al.
Published: (2021)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
by: Labib A, et al.
Published: (2022)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
by: Sandoval LF, et al.
Published: (2015)

Management of psoriasis in pregnancy - a review of the evidence to date
by: Clara Ferreira, et al.
Published: (2020)

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
by: Vivian Jiang, et al.
Published: (2024)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor
by: Zhou-Peng Xiao, et al.
Published: (2023)

New approaches in the management of multiple sclerosis
by: Laurie J Barten, et al.
Published: (2010)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022)

Inflammation and physical activity in multiple sclerosis patients. A systematic review and meta-analysis
by: V. Bellisario, et al.
Published: (2024)

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
by: Andreas Becker, et al.
Published: (2020)

Assessing cost-effectiveness in the management of multiple sclerosis
by: Ceri J Phillips, et al.
Published: (2009)

Patient's perspective in multiple sclerosis for spiritual healing
by: Nisha Gupta
Published: (2021)

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
by: Timothy D. Owens, et al.
Published: (2022)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
by: Cao T, et al.
Published: (2022)

Digital innovation in Multiple Sclerosis Management
Published: (2022)

QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors
by: Mourad Aloui, et al.
Published: (2024)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
by: Alkabbani W, et al.
Published: (2021)

A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date
by: Peitsidis P, et al.
Published: (2023)

Participant Perspectives on Community Qigong for People with Multiple Sclerosis
by: Lita Buttolph, et al.
Published: (2023)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
by: Jia Liu, et al.
Published: (2022)

Exploring the efficacy of cannabinoids in the management of multiple sclerosis
by: Aleksandra Rykucka, et al.
Published: (2024)

THE PROBLEM OF NEUTRALIZING ANTIBODIES IN MANAGEMENT OF MULTIPLE SCLEROSIS
by: B.I. Bursagova, et al.
Published: (2011)

THE PROBLEM OF NEUTRALIZING ANTIBODIES IN MANAGEMENT OF MULTIPLE SCLEROSIS
by: B.I. Bursagova, et al.
Published: (2011)

Progress in the Management of Paediatric-Onset Multiple Sclerosis
by: Aphra Luchesa Smith, et al.
Published: (2020)